Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Launched by UNIVERSITY HOSPITAL, CAEN · Jan 24, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether the risk of developing atrial fibrillation (a heart rhythm problem) is related to the dose of ibrutinib, a medication commonly used to treat certain blood cancers like chronic lymphocytic leukemia (CLL). Atrial fibrillation has been noted as a potential side effect of ibrutinib, but researchers want to understand if taking higher doses increases this risk. To do this, they will look at patient reports in a global health database to see if there's a connection between the amount of ibrutinib taken and the occurrence of atrial fibrillation.

The trial is open to adults aged 65 to 74 who have experienced atrial fibrillation linked to ibrutinib and for whom information about their medication dosage is available. Unfortunately, younger individuals and those without a recorded dose of ibrutinib won't be eligible to participate. While the trial is not yet recruiting participants, those who join can help researchers better understand the safety of ibrutinib and potentially improve treatment guidelines for patients taking this important medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ibrutinib-related atrial fibrillation reports in Vigibase at the time of data extraction
• • involving adult patients
• • with an available ibrutinib daily dose
• Exclusion Criteria:
• • minors
• • no ibrutinib dose available